Perhaps a new day is dawning as J&J and Yale have crafted a deal to make J&J's raw clinical trial data much more available to independent researchers. The deal as stated by Harlan Krumholz, professor of medicine at Yale, calls for J&J to make its data available in response to valid scientific requests. Under the terms, this disclosure is NOT to be used for commercial or litigious purposes. An independent panel at Yale will review requests with no direct J&J involvement in the review -- an unusual feature compared to other programs of this type.
At least one transparency advocate, Stephen Friend, former Merck Exec, wants to remain cautiously optimistic until he sees how the program works in practice. How close does it walk the talk as it were. Joanne Waldstreicher, J&J''s chief medical officer, says the company is dong this to advance science, and "always believed in the transparency of our data." We'll all get to see now. And like most things in the pharmaceutical world, if this program is successful other companies will be sure to follow whether by choice or peer pressure. See Xconomy.
Posted by Bruce Lehr Jan 30th 2014.